Janus kinase 1, Janus kinase 2, Janus kinase 3 (JAK1, JAK2, JAK3)

Janus kinase 1, Janus kinase 2, and Janus kinase 3 (collectively known as JAK1, JAK2, and JAK3) are intracellular, non-receptor tyrosine kinases that serve as essential mediators of cytokine signaling through the JAK-STAT pathway. Each JAK binds to specific subunits of cytokine receptors; activation leads to phosphorylation of STAT transcription factors and modulation of gene expression. JAK1 and JAK2 are broadly expressed, while JAK3 expression is predominantly restricted to hematopoietic and immune cells. Dysregulation of JAK activity is implicated in numerous diseases, including hematologic malignancies, autoimmune disorders, and inflammatory conditions. Therapeutic inhibition of these kinases represents an established strategy for treating conditions such as rheumatoid arthritis, myelofibrosis, and other immune-mediated diseases[1][2][3][5].

Other names

JAK family kinasesJanus kinasesNon-receptor tyrosine-protein kinase JAK1/JAK2/JAK3JAKs

Inhibition of JAK kinase catalytic activity; Blockade of cytokine-mediated signal transduction via the JAK-STAT pathway; Disruption of STAT transcription factor activation